New transplant strategy aims to cure devastating immune disease

NCT ID NCT05463133

Recruiting now Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

Summary

This study is testing a new drug combination given before a stem cell transplant to improve the procedure's success for people with Chronic Granulomatous Disease (CGD). CGD is a serious immune disorder that causes frequent infections. The trial aims to help the donor stem cells take hold better and reduce dangerous inflammation, which has been a major problem, especially for patients with high inflammation levels. It is for people aged 4 to 65 with CGD.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GRANULOMATOUS DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CHRONIC GRANULOMATOUS DISEASE